Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2005

View Archived Issues

Baseline lipid profile may help predict treatment outcome in hepatitis C patients

Exisulind does not inhibit duodenal adenoma growth in FAP patients

Atilmotin speeds gastrointestinal transit in humans

A-425619: a TRPV1 antagonist with antinociceptive effects / News in Context

Phase II data support the use of squalamine lactate in AMD

Enrollment begins in phase II colorectal cancer study of Davanat/5-FU

Favorable pharmacokinetic and therapeutic profile of PL-100 prodrug PPL-100

scFvCD7:sTRAIL causes restricted apoptosis in human leukemic T-cells

Alferon LDO being studied in clinical trials for viral diseases

Phase I/II study for SPC-2996 in CLL

Abstracts describe efficacy of DX-88 in HAE

Phase II/III results with recombinant human C1 inhibitor in HAE

NanoCure changes name to Avidimer Therapeutics

ECO-4601 shows in vivo efficacy against prostate and breast cancers

Phase III study of NGX-4010 in HIV-associated neuropathy meets endpoint

Tranzyme Pharma completes private financing round

Phase II data on MDX-010/dacarbazine combination therapy for metastatic melanoma

MethylGene discloses target of angiogenesis inhibitor

Neurologix licenses humanin gene with potential CNS disorder therapy application

Takara Bio obtains rights to gene therapy

Virulizin enhances IL-17E to propagate tumor destruction

Recent patents report potential new treatments for anxiety, depression, psychosis, etc.

Recent Japan Tobacco patent describes new antihepatitis C agents

New anticoagulants under development at TransTech Pharma

Thrombopoietin, erythropoietin receptor agonists revealed in patent literature

Prolonged infusion reduces toxicity of kahalalide F in patients with solid tumors

Good safety profile of ixabepilone in Japanese patients with solid tumors

Tipranavir recommended for accelerated approval by FDA Advisory Committee

FDA approves extended indication of Atacand for treatment of heart failure

Dainippon and Sumitomo to merge in 4th quarter 2005

FDA approves Proquin XR for uncomplicated urinary tract infections

Potent activity of new broad-spectrum fluoroquinolone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...